It is good to see the FDA taking quick and firm action against companies improperly marketing their CBD products as effective against COVID-19, a devastating pandemic with no contemporary precedent.
The American Journal of Endocannabinoid Medicine (AJEM) is the only printed, peer-reviewed, medical cannabis journal in North America. AJEM’s mission is to create, collect, and disseminate credible cannabis research data.
As a service to our current clients and readers during these difficult times, we are offering a free 20-minute phone call to address your pressing issues – no strings attached.
For my talk, I compared and contrasted the hemp and CBD regulatory regimes in Europe and US. Although they parallel each other in some respects, particularly policy, they are fundamentally different in their approaches.
The FDA has yet to create a regulatory pathway for CBD. Does its most recent report to Congress herald a change?
Although the DOT Notice regarding drug testing purports to clarify the law with respect to a certain category of “safety-sensitive” employees, it really just muddies the water.
This second installment of a two-part series discusses important things to know when stopped in public by law enforcement while transporting hemp or a hemp-derived product.
This first installment of a two-part series covers important things to know in general about being stopped in public by law enforcement while in possession of hemp or a hemp-derived product.
Some NC legislators may decide that it is not in their best interests in an election year to vote in favor of a bill that their constituents actively oppose. If SB315 does not become law then there may be no mechanism to propose a plan to the USDA and hemp production will be regulated by the USDA next year.
Enacting this Bill into law could be a game-changer in that it will expressly authorize CBD in food and as a dietary supplement; however, passage in the Senate is far from a foregone conclusion.